

AMENDMENTS TO THE CLAIMS

Claims 1-15 (canceled)

Claim 16 (canceled)

Claim 17 (canceled)

Claim 18 (canceled)

Claim 19 (canceled)

Claim 20 (canceled)

21. (new) Oxacarbazepine having improved bioavailability, wherein said oxacarbazepine has a maximum residue on a 40 μm sieve of less than or equal to 5%.

22. (new) The oxacarbazepine of claim 21, wherein said oxacarbazepine has a maximum residue on a 40 μm sieve of less than or equal to 2%.

23. (new) Oxacarbazepine having improved bioavailability, wherein said oxacarbazepine has a median particle size of approximately from 2 μm to 12 μm .

24. (new) The oxacarbazepine of claim 23, wherein said median particle size is approximately from 4 μm to 10 μm .

25. (new) The oxacarbazepine of claim 23, wherein said median particle size is approximately from 6 μm to 8 μm .

26. (new) A formulation which comprises oxacarbazepine having improved bioavailability, wherein said oxacarbazepine has a maximum residue on a 40 μm sieve of less than or equal to 5%.

27. (new) The formulation of claim 26, wherein said maximum residue on a 40 μm sieve is less than or equal to 2%.

28. (new) The formulation of claim 26, wherein said formulation further contains one or more pharmaceutically acceptable excipients.

29. (new) The formulation of claim 26, wherein said formulation is a solid oral dosage form.

30. (new) The formulation of claim 29, wherein said solid oral dosage form is a tablet.
31. (new) The formulation of claim 30, wherein said tablet is film coated.
32. (new) The formulation of claim 31, wherein said film coating is a hydrophilic permeable outer coating.
33. (new) A formulation which comprises oxacarbazepine having improved bioavailability, wherein said oxacarbazepine has a median particle size of approximately from 2 μm to 12 μm .
34. (new) The formulation of claim 33, wherein said median particle size is approximately from 4 μm to 10 μm .
35. (new) The formulation of claim 34, wherein said median particle size is approximately from 6 μm to 8 μm .